What is the Cost Effectiveness of High-Dose Statin Therapy in High-Risk Patients with Coronary Artery Disease? Recent clinical trials found that high-dose statin therapy, compared with conventional-dose statin therapy, reduces the risk of cardiovascular events in patients with acute coronary syndromes (ACS) and stable coronary artery disease (CAD). However, the actual benefits and cost-effectiveness of high-dose statin therapy are still unknown. What can we deduct from this analysis, and will it affect how and when we prescribe high-does statins to our patients?
Main Findings and Implications of "Cost Effectiveness of High-Dose Statin Therapy in High-Risk Patients with Coronary Artery Disease" Study
Restart
Resume
Transcript
Main Findings and Implications of "Cost Effectiveness of High-Dose Statin Therapy in High-Risk Patients with Coronary Artery Disease" Study
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
What is the Cost Effectiveness of High-Dose Statin Therapy in High-Risk Patients with Coronary Artery Disease? Recent clinical trials found that high-dose statin therapy, compared with conventional-dose statin therapy, reduces the risk of cardiovascular events in patients with acute coronary syndromes (ACS) and stable coronary artery disease (CAD). However, the actual benefits and cost-effectiveness of high-dose statin therapy are still unknown. What can we deduct from this analysis, and will it affect how and when we prescribe high-does statins to our patients?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
MinuteCE®
Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type
1.00 credits
<p><span data-contrast="none" xml:lang="EN-US">Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type</span> </p>
Perspectives with the AMA
Implementing the AMA MAPTM Hypertension Program: A Clinician’s Experience
<p>Implementing the AMA MAP™ Hypertension Program: A Clinician's Experience</p>
MinuteCE®
Biomarkers of the Storm: Decoding IRI’s Signature
0.50 credits
<p>Biomarkers of the Storm: Decoding IRI’s Signature</p>
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 credits
<p>Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 credits
<p>Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?